Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Part of paid clinical trials in Orange, California.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT07101094
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- xanomeline and trospium chloride (X/T) therapy — DRUGAccording to the product label
Study Details
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
Key Dates
- Start date
- Sep 22, 2025
- Status verified
- May 2026
- Primary completion
- Jan 31, 2029
- Completion
- May 14, 2029
Study Design
- Enrollment
- 300 participants (estimated)
Arms
- Arm: Participants receiving xanomeline and trospium chloride (X/T) therapy
Primary Outcome Measure
Participant medication preference as assessed by the Preference of Medication (POM) questionnaire [ Time Frame: Month 1, Month 3, Month 6 ]
Central Contacts
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
- First line of the email MUST contain NCT # and Site #.
Locations (18)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Local Institution - 0009 | Orange | California | 92868 | Site 0009 |
| Lumos Clinical Research Center | San Jose | California | 95124 | Sarbani Maitra, Site 0010 408-668-2712 |
| Local Institution - 0003 | Evanston | Illinois | 60201 | Site 0003 |
| Local Institution - 0007 | Baltimore | Maryland | 21287 | Site 0007 |
| Local Institution - 0017 | Bel Air | Maryland | 21015 | Site 0017 |
| Local Institution - 0004 | Catonsville | Maryland | 21228 | - |
| Local Institution - 0008 | Belmont | Massachusetts | 02478-1064 | Site 0008 |
| Local Institution - 0002 | Boston | Massachusetts | 02118 | Site 0002 |
| Mayflower Clinical | South Dartmouth | Massachusetts | 02747 | Simon Desjardins, Site 0011 |
| Omaha Insomnia and Psychiatric Services | Omaha | Nebraska | 68144 | Vithya Selvaraj, Site 0005 402-991-9630 |
| Hackensack Meridian Health - Carrier Clinic | Belle Mead | New Jersey | 08502 | Stacy Doumas, Site 0001 |
| Radial - Manhattan | New York | New York | 10018 | Owen Muir, Site 0015 929-260-5003 |
| New Dawn Psychiatric Services, PLLC | Kinston | North Carolina | 28501 | Punitha Rathnam, Site 0016 252-686-8091 |
| Local Institution - 0018 | Rose Hill | North Carolina | 28458 | Site 0018 |
| Westlake Brain Health | Westlake | Ohio | 44145 | Abdelrahman Abdelaziz, Site 0014 317-560-2391 |
| Continuum Health Providers | Fort Mill | South Carolina | 29708 | Brian Mika, Site 0006 |
| Haracec Clinical Research | El Paso | Texas | 79902 | Aghaegbulam Uga, Site 0012 |
| Local Institution - 0013 | Longview | Texas | 75601 | Site 0013 |
Find similar trials in Orange, CA
By condition
By specialty
Related Studies
- Database Registry for Neural Network Biomarkers in PsychosisRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With SchizophreniaPHASE3 · Recruiting · Gedeon Richter Plc. · Culver City, California
- Ocrelizumab for Psychosis by AutoimmunityPHASE1/PHASE2 · Recruiting · The Methodist Hospital Research Institute · Houston, Texas
- Imaging Synapses With [11C] UCB-J in the Human BrainPHASE1 · Recruiting · Davidzon, Guido, M.D. · Palo Alto, California